The Division was established to guarantee the best of care to patients with thoracic malignancies; a dedicated staff takes care of the patient in each stage of disease. The clinical practice of the Division consists of in- and outpatients treatment, according to the complexity of the therapy, and of consultations for second opinions.
The principal fields of interest of the Division of Thoraric Oncology include phase 2 and phase 3 trial on non-small-cell lung cancer with EGFR mutations and ALK translocation in first, second and other lines of treatment. In addition, at the present time, we have different available clinical trial evaluating target agents against MET, ROS1, HER2, and BRAF over the first-line setting. In addiction to the development of the previous discussed target agents, in this latter period we are able to enrolled patients in multiple and extremely promising clinical trial for advanced, adjuvant and neo-adjuvant setting using immune check-point inhibitor as anti-PD1 and PD-L1 drug, in squamous and adenocarcinoma of the lung.
In this year, the Division of Thoracic Oncology treated about 600 patients with lung cancer, in neo-adjuvant setting to improve results or a sequent surgery; in adjuvant, after surgery to improve outcome and minimize recurrence of disease. Patients with locally advanced disease were treated with a concomitant radiation therapy and chemotherapy.
Every single patients was treated based on a multidisciplinary approach, that improve results and maximize adherence to proposed treatment. Patients with metastatic setting benefit of different kind of treatment with chemotherapy, target agents or immune check point inhibitor, managed from physicians with a high grade of experience.
The Division of Thoracic Oncology is not only a corner stone for patients with non-small-cell lung cancer, but also for patients with neuroendocrine tumors of the lung and mesothelioma, that could benefit of a trimodality approach with chemotherapy, radiation therapy and surgery.
The Division of Thoracic Oncology is devoted to improve survival and quality of life of every patients with lung cancer treated at IEO.